Explore

Trendline Trendline
Bruntwood SciTech and Cellular Origins Sign Landmark Deal for Cell Therapy Manufacturing Expansion

Bruntwood SciTech and Cellular Origins Sign Landmark Deal for Cell Therapy Manufacturing Expansion

Bruntwood SciTech and Cellular Origins Sign Landmark Deal for Cell Therapy Manufacturing Expansion
Trendline Trendline
Biotech Companies Secure Major Funding to Advance Cancer Treatments

Biotech Companies Secure Major Funding to Advance Cancer Treatments

Biotech Companies Secure Major Funding to Advance Cancer Treatments
Rapid Read Rapid Read
UK Achieves Target in Reducing Clinical Trial Set-Up Times, Boosting Life Sciences

UK Achieves Target in Reducing Clinical Trial Set-Up Times, Boosting Life Sciences

The UK has successfully reduced the average set-up time for clinical trials to 122 days, down from 169 days in the previous year, according to the National Institute for Health and Care Research (NIHR). This achievement meets the government's target of 150 days by March 2026, aimed at making the UK a more attractive location for life sciences companies to conduct trials. The reduction in set-up times is attributed to streamlined processes, including standardized commercial contracting across the NHS and the establishment of the NIHR Life Sciences Industry Hub. Despite this progress, challenges such as low patient recruitment rates and rising costs continue to affect the sector.
Trendline Trendline
STORM Therapeutics Raises $56M for RNA-Targeting Cancer Drug Development

STORM Therapeutics Raises $56M for RNA-Targeting Cancer Drug Development

STORM Therapeutics Raises $56M for RNA-Targeting Cancer Drug Development
Trendline Trendline
STORM Therapeutics Secures $56M for Cancer Drug Development

STORM Therapeutics Secures $56M for Cancer Drug Development

STORM Therapeutics Secures $56M for Cancer Drug Development
Trendline Trendline
UK Healthtech Sector Boosted by £100 Million Investment from National Bank

UK Healthtech Sector Boosted by £100 Million Investment from National Bank

UK Healthtech Sector Boosted by £100 Million Investment from National Bank
Rapid Read Rapid Read
UK Healthtech Sector Boosted by £100M Investment from British Business Bank

UK Healthtech Sector Boosted by £100M Investment from British Business Bank

The British Business Bank has committed £100 million to a new healthcare fund launched by Apposite Capital, aimed at supporting innovative UK companies in the life sciences sector. The Apposite Healthcare Growth I fund targets companies involved in medical products, diagnostics, digital health, and pharmaceutical services. This investment is the bank's largest to date and seeks to address the capital shortage for companies at a growth inflection point. The initiative aligns with the UK's Life Sciences Sector Plan, aiming to position the UK as a leading life sciences hub by 2030.
Trendline Trendline
Fieldwork Robotics Partners with Dynium to Enhance Autonomous Harvesting Robots

Fieldwork Robotics Partners with Dynium to Enhance Autonomous Harvesting Robots

Fieldwork Robotics Partners with Dynium to Enhance Autonomous Harvesting Robots
Rapid Read Rapid Read
UK Achieves Target in Reducing Clinical Trial Set-Up Times, Enhancing Research Competitiveness

UK Achieves Target in Reducing Clinical Trial Set-Up Times, Enhancing Research Competitiveness

The United Kingdom has successfully reduced the average set-up time for clinical trials to 122 days, down from 169 days in the previous year, according to the National Institute for Health and Care Research (NIHR). This achievement meets the government's target of reducing trial set-up times to an average of 150 days by March 2026. The reduction is attributed to efforts in cutting red tape and standardizing commercial contracting processes across the NHS. The NIHR Life Sciences Industry Hub has also been instrumental in streamlining processes for companies conducting trials in England. Despite this progress, challenges such as low patient recruitment rates and rising costs continue to affect the UK's position as a hub for clinical research.
Rapid Read Rapid Read
BIO Asia-Taiwan 2026 to Highlight AI Integration in Biotech Commercialization

BIO Asia-Taiwan 2026 to Highlight AI Integration in Biotech Commercialization

The annual BIO Asia-Taiwan 2026 event is set to take place from July 15 to 19 at the Taipei Nangang Exhibition Center. Organized by the Taiwan Bio Industry Organization and the Biotechnology Innovation Organization, the event will focus on the theme 'Asian Inspiration, Global Impact.' This year's conference will emphasize the role of artificial intelligence in accelerating biotech commercialization, showcasing Asia's strengths in biomedicine and expanding international participation. The event will feature over 2,200 exhibition booths and participation from more than 20 countries. Key highlights include forums on research innovation, investment, regulation, and supply chains, as well as business matchmaking sessions expected to exceed 10,000 meetings.
Trendline Trendline
British Business Bank Invests £100 Million in Apposite Capital's Healthcare Fund to Boost UK Life Sciences

British Business Bank Invests £100 Million in Apposite Capital's Healthcare Fund to Boost UK Life Sciences

British Business Bank Invests £100 Million in Apposite Capital's Healthcare Fund to Boost UK Life Sciences
Trendline Trendline
Cell and Gene Therapy CDMO Market Projected to Reach $125 Billion by 2035

Cell and Gene Therapy CDMO Market Projected to Reach $125 Billion by 2035

Cell and Gene Therapy CDMO Market Projected to Reach $125 Billion by 2035